	US 11,850,265 B2
	Treatment and prophylaxis of radiation dermatitis
Mark Lait, Hertford (GB); and George Bishop, Carlstadt, NJ (US)
Assigned to RADIADERM LIMITED, London (GB)
Filed by RADIADERM LIMITED, London (GB)
Filed on Sep. 25, 2020, as Appl. No. 17/033,294.
Application 15/988,159 is a division of application No. 14/772,139, granted, now 10,098,912, previously published as PCT/EP2014/054319, filed on Mar. 6, 2014.
Application 17/033,294 is a continuation of application No. 15/988,159, filed on May 24, 2018, abandoned.
Claims priority of provisional application 61/773,225, filed on Mar. 6, 2013.
Claims priority of application No. 1304041 (GB), filed on Mar. 6, 2013.
Prior Publication US 2021/0008116 A1, Jan. 14, 2021
Int. Cl. A61K 35/20 (2006.01); A61K 9/06 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 47/46 (2006.01); A61K 31/047 (2006.01); A61K 31/12 (2006.01); A61K 31/133 (2006.01); A61K 31/216 (2006.01); A61K 31/275 (2006.01); A61K 38/01 (2006.01)

CPC A61K 35/20 (2013.01) [A61K 9/0009 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/047 (2013.01); A61K 31/12 (2013.01); A61K 31/133 (2013.01); A61K 31/216 (2013.01); A61K 31/275 (2013.01); A61K 38/018 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/18 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/46 (2013.01)]

17 Claims

1. A process for addressing radiation dermatitis comprising the steps of:

a) applying a layer of hydrogel to unbroken skin following radiation therapy and leaving the hydrogel thereon for at least 20 minutes; and

b) applying lotion to the unbroken skin to provide moisturisation;

wherein step b) is repeated as often as desired to relieve discomfort;

wherein the hydrogel is a topical formulation comprising purified water, milk protein fluid and thickener, and one or more ingredients selected from: a polyacrylic acid, pH modifier, and moisturising agent;

wherein the lotion is a topical formulation comprising purified water, milk protein fluid and thickener, and one or more ingredients selected from: non-metallic UVA inhibitor, non-metallic UVB inhibitor, a skin conditioning agent, emulsifier, gelling agent, solvent, mineral oil, pH modifier and phosphate buffer; and

wherein the lotion consists essentially of:

7-19% weight/weight (w/w) non-metallic UVA or UVB inhibitor,

54.5-65.5% w/w purified water,

6-15% w/w C 12-15 alkyl benzoate,

4-8% w/w milk protein fluid,

1-5% w/w caprylyl methicone,

1-2.5% w/w emulsifier,

0.25-1.25% w/w gelling agent,

1-2.5% w/w glyceryl monostearate,

1-2.5% w/w glyceryl stearate citrate,

0.5-1.2% w/w preservative,

0-1% w/w edetate disodium, and

2% w/w thickener.